Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Theratechnologies Inc T.TH

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  THERF

Theratechnologies Inc is a pharmaceutical company addressing unmet medical needs in metabolic disorders. EGRIFTA is its registered trademark in the USA and it is used to commercialize its first product using its internally developed compound, tesamorelin.
Price: $1.60 | Change: $-0.12 | %Change: -6.98%
Volume: 516,657 | Day High/Low: 1.75/1.58 | 52 Week High/Low: 1.85/0.325
View modes: 
0 stars

dip buy

maybe 1.40s-1.50s.  rate and reply
0 stars

Greece - Weaker Canadian $ Benefits TH

Since almost all of TH's revenues are US dollar based and a good chunk of their costs are Canadian $ based, a weaker Canadian dollar has been, and may continue to given the Greek situation, benefit TH...read more
0 stars

RE:RE:RE:RE:RE:US potential

I am not sure when this was posted but it gives some insights into the Egrifta/Serostrim issue. Clearly it was posted before TH took control of the US marketing rights to Egrifta from Serono. http...read more
0 stars

RE:RE:RE:RE:US potential

Still, Serostim is not approved for the treatment of lipodistrophy, so no reimbursment by insurance companies for off label use.  rate and reply
0 stars

RE:RE:RE:US potential

Make no mistake, Serostrim has been used by doctors to treat lipodystrophy. In the first attempt to market Egrifta, this was apparently a headwind to Egrifta sales. Needless to say, Serono's full...read more
0 stars

RE:RE:RE:RE:US potential

The current corporate presentation has what the company is projecting the current market size as, which is considerably smaller and more realistic than the hopes seen in 2007. Obviously, it is not as...read more
0 stars

RE:RE:RE:US potential

An update would be helpful http://theratech.com/sites/default/files/news_release_en/th-12102007-en.pdf  rate and reply
0 stars

RE:RE:US potential

Serostim is not approved for HIV lipodystrophy. So I don't see how a patient with this condition would prefer Serostim over Egrifta. Serostim price is higher and it cannot be reimbursed by insurance...read more
0 stars

RE:US potential

You are right about this being a, if not the, key question for TH shareholders. If they get 5,000 patients, then everyone who owns the stock is going to be taking very nice vacations in the next few...read more
0 stars

RE:US potential

Don't forget that Egriffta is the sole approved treatment for that indication. So, in theory, it could achieve 100% market penetration.  rate and reply
0 stars

US potential

I think the major unknown for Thera is the realistic maximum number of patients on the drug that can be achieved. We still don't know if Serono was doing a poor job with this drug. Beyond the peak...read more
0 stars

RE:RE:RE:RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

The market probably should assign some tiny probability of success at this point but also probably won't. At least not until closer to when the first test results are imminent. Since the company is...read more
0 stars

RE:RE:RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

Even if the market attributed a 15-20% chance of working, and it did receive funding from the NIH, that chance alone could add significantly to the share price given the revenue potential.  rate and reply
0 stars

RE:RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

In my estimation, there will not be any appreciation for this trial until the first results are published and that is probably more than a year away. Grinspoon must feel there is some reason to...read more
0 stars

RE:RE:RE:RE:RE:RE:RE:RE:3Q and 4Q Expectations

And happy belated Canada Day to you!  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:RE:3Q and 4Q Expectations

Very good post SPCE01 BTW my Nick name is PALINC not PALIN Indeed I do not live in Wasilla and I cannot see Russia from my house !!LOL Happy 4 th of July long weekend  rate and reply
5 stars

RE:RE:RE:RE:RE:RE:3Q and 4Q Expectations

A few copmments: 1.) Sales were reported by Bloomberg today and the 4 week average hit a new high. I would love to share specifics but I think that is fas far as I should go.  2.) Don't know how...read more
0 stars

RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

We didn't get a lift in the share price when it was announced but the new trial paid for by the NIH would be transformative in a very substantial way if successful given the rate of non-fatty liver...read more
0 stars

Institutions quietly buying this stock

If you look at the trades, insitutions are picking up all the shares at $1.80.  No news and the stock is slowly going up.  Love it.  rate and reply
0 stars

RE:RE:RE:RE:RE:3Q and 4Q Expectations

It think if Mr. Murphy stays away then the $10/share would be reachable.  We have seen some insider buying and Rusty mentioned that the Bloomberg numbers look good.  But I would actually like to see...read more